Predictive Oncology Inc. announced the appointment of Matthew J. Hawryluk, Ph.D. to its Board of Directors to help support the company's strategic initiatives and commercialization efforts. Dr. Hawryluk currently serves as Executive Vice President and Chief Business Officer of Gritstone bio Inc. Recognized by Pharmaceutical Executive magazine as a leading business executive in the pharma and biotech industries, Dr. Hawryluk has played key roles in bridging the gap between scientific discovery and the commercial application of scientific breakthroughs. As a named inventor on multiple patents and co-author on several peer-reviewed publications, he brings an awareness and insight to Predictive Oncology that will be instrumental as the company moves forward with its growth plans.

Before joining Gritstone, Dr. Hawryluk served as Vice President of Corporate and Business Development at Foundation Medicine Inc., a public molecular information company (subsequently acquired by Roche), and before then assumed roles in business development, marketing and product management across multiple divisions of Thermo Fisher Scientific Inc. In addition to his Board role with Predictive Oncology, Dr. Hawryluk serves as an Advisory Board Member of PathAI Inc. Dr. Hawryluk holds a Ph.D. in cell biology and protein biochemistry from the University of Pittsburgh School of Medicine, an M.B.A. from Carnegie Mellon University's Tepper School of Business and B.S. from the University of Notre Dame.